Kite Pharma

Executive Summary

Kite Pharma, a Gilead Sciences subsidiary headquartered in Amsterdam, is a leader in autologous CAR T-cell therapy for hematologic malignancies. With approved therapies Yescarta and Tecartus, Kite has treated thousands of patients and generated significant revenue. The company's platform enables engineering of patient-derived T cells to target CD19, achieving durable remissions in aggressive lymphomas and leukemias. Looking ahead, Kite is advancing next-generation CAR T programs aimed at improving efficacy, safety, and expanding into solid tumors. Key pipeline candidates include a BCMA-targeted therapy for multiple myeloma and novel constructs with armored or logic-gated designs. The company also explores allogeneic approaches and combination trials to overcome resistance. Kite's established manufacturing and commercialization infrastructure position it well for sustained growth.

Upcoming Catalysts (preview)

• Q3 2026Yescarta label expansion to first-line high-risk large B-cell lymphoma70% success
• Q4 2026Phase 2 data for KITE-363 (BCMA CAR T) in multiple myeloma55% success
• Q2 2026FDA approval of Tecartus for pediatric acute lymphoblastic leukemia80% success